Biohaven secures $250 million from Oberland Capital, with total cash reaching $518 million to support troriluzole launch and operations.
Latest Ratings for BHVN
Date | Firm | Action | From | To |
---|
Mar 2022 | Mizuho | Maintains | | Buy |
Jan 2022 | Morgan Stanley | Maintains | | Equal-Weight |
Nov 2021 | Mizuho | Maintains | | Buy |
View More Analyst Ratings for BHVN
View the Latest Analyst Ratings
read more